Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
15
RXRX Quote, Financials, Valuation and Earnings
Last price:
$4.41
Seasonality move
:
-16.61%
Day range:
$4.30 - $4.43
52-week range:
$3.79 - $12.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
40.00x
P/B ratio:
2.17x
Volume:
26M
Avg. volume:
24.7M
1-year change:
-37.63%
Market cap:
$2.3B
Revenue:
$58.8M
EPS (TTM):
-$1.81
Analysts' Opinion
-
Consensus RatingRecursion Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Recursion Pharmaceuticals, Inc. has an estimated upside of 60.55% from its current price of $4.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $4.36.
Fair Value
-
According to the consensus of 6 analysts, Recursion Pharmaceuticals, Inc. has 60.55% upside to fair value with a price target of $7.00 per share.
RXRX vs. S&P 500
-
Over the past 5 trading days, Recursion Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Recursion Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Recursion Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Recursion Pharmaceuticals, Inc. reported revenues of $5.2M.
Earnings Growth
-
Recursion Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Recursion Pharmaceuticals, Inc. reported earnings per share of -$0.36.
Enterprise value:
1.7B
EV / Invested capital:
1.50x
Price / LTM sales:
40.00x
EV / EBIT:
--
EV / Revenue:
38.65x
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
-3.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$70.1M
Return On Assets:
-57.87%
Net Income Margin (TTM):
-1637.81%
Return On Equity:
-80.23%
Return On Invested Capital:
-72.69%
Operating Margin:
-3327.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $47.4M | $65.2M | $43.7M | $26.1M | $5.2M | |
| Gross Profit | -$1.5M | -$2.1M | -$70.1M | $9.9M | -$22.9M | |
| Operating Income | -$312.1M | -$404.4M | -$723.6M | -$98.4M | -$172.2M | |
| EBITDA | -$286.1M | -$365.3M | -$646.2M | -$90.3M | -$151.2M | |
| Diluted EPS | -$1.47 | -$1.53 | -$1.81 | -$0.34 | -$0.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $600.9M | $481.6M | $402.6M | $474.2M | $714.1M | |
| Total Assets | $658.6M | $611.5M | $630.8M | $726.5M | $1.4B | |
| Current Liabilities | $42.9M | $83M | $94.1M | $108.9M | $155.1M | |
| Total Liabilities | $59.6M | $223.5M | $192.9M | $201.9M | $352.6M | |
| Total Equity | $599M | $388M | $438M | $524.6M | $1B | |
| Total Debt | $5.6M | $46.6M | $46.1M | $82.4M | $70.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$258.5M | -$317.8M | -$441.2M | -$59.2M | -$117.4M | |
| Cash From Investing | -$15.7M | -$17.9M | $259.8M | -$4.6M | -$2.5M | |
| Cash From Financing | $206.7M | $374.1M | $400.2M | $16.5M | $251.3M | |
| Free Cash Flow | -$276.6M | -$335.6M | -$450.2M | -$63.8M | -$117.6M | |
RXRX
Sector
Market Cap
$2.3B
$28.1M
Price % of 52-Week High
35.28%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-17.08%
-1.49%
1-Year Price Total Return
-37.63%
-17.13%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.36
200-day SMA
Sell
Level
$5.15
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.51
Relative Strength Index (RSI14)
Sell
Level
46.79
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-76.8397
50-day SMA
Sell
Level
$4.93
MACD (12, 26)
Buy
Level
1.08
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
--
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8889)
Sell
CA Score
(Annual)
Level (-1.5218)
Buy
Beneish M-Score
(Annual)
Level (-3.3494)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.5063)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Stock Forecast FAQ
In the current month, RXRX has received 1 Buy ratings 5 Hold ratings, and 0 Sell ratings. The RXRX average analyst price target in the past 3 months is $7.00.
-
Where Will Recursion Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Recursion Pharmaceuticals, Inc. share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Recursion Pharmaceuticals, Inc.?
Analysts are divided on their view about Recursion Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Recursion Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Recursion Pharmaceuticals, Inc.'s Price Target?
The price target for Recursion Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $7.00 according to 6 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is RXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Recursion Pharmaceuticals, Inc. is a Hold. 5 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RXRX?
You can purchase shares of Recursion Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Recursion Pharmaceuticals, Inc. shares.
-
What Is The Recursion Pharmaceuticals, Inc. Share Price Today?
Recursion Pharmaceuticals, Inc. was last trading at $4.41 per share. This represents the most recent stock quote for Recursion Pharmaceuticals, Inc.. Yesterday, Recursion Pharmaceuticals, Inc. closed at $4.36 per share.
-
How To Buy Recursion Pharmaceuticals, Inc. Stock Online?
In order to purchase Recursion Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RXRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RXRX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.13x
-0.01x
P/B ratio
2.17x
1.81x
Price / LTM sales
40.00x
1.59x
Growth Metrics
RXRX
Sector
Revenue growth
-80.16%
4.62%
Earnings growth
-7.02%
11.06%
Revenue (5-year growth)
90.93%
6.5%
Earnings forecast
-$0.38
-$0.21
Profitability
RXRX
Sector
Profitability FY 2024
-$4.6M
$3.6M
Return on invested capital
-72.69%
-31.84%
Return on assets
-57.87%
-27.96%
Return on equity
-80.23%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
RXRX
Sector
Total cash
$663M
$26.4M
Short term investments
--
$25.7M
Total assets
$1.4B
$76.9M
Long term debt
$70.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
